Monoclonal antibody 170

Drug Profile

Monoclonal antibody 170

Alternative Names: Tru-Scint AD

Latest Information Update: 28 Jun 2011

Price : $50

At a glance

  • Originator Biomira
  • Class Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 13 May 2003 Monoclonal antibody 170 is available for licensing (http://www.biomira.com)
  • 04 Sep 2001 Discontinued-II for Ovarian cancer (diagnosis) in Germany (Injection)
  • 04 Sep 2001 Discontinued - Phase-II/III for Breast cancer (diagnosis, recurrent) in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top